SWTX vs. SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, PCVX, and QGEN
Should you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), Vaxcyte (PCVX), and Qiagen (QGEN). These companies are all part of the "pharmaceutical products" industry.
SpringWorks Therapeutics vs.
SpringWorks Therapeutics (NASDAQ:SWTX) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.
SpringWorks Therapeutics has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than SpringWorks Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Summit Therapeutics had 4 more articles in the media than SpringWorks Therapeutics. MarketBeat recorded 11 mentions for Summit Therapeutics and 7 mentions for SpringWorks Therapeutics. SpringWorks Therapeutics' average media sentiment score of 0.93 beat Summit Therapeutics' score of 0.68 indicating that SpringWorks Therapeutics is being referred to more favorably in the media.
SpringWorks Therapeutics currently has a consensus target price of $73.20, suggesting a potential upside of 55.05%. Summit Therapeutics has a consensus target price of $34.11, suggesting a potential upside of 68.53%. Given Summit Therapeutics' higher probable upside, analysts clearly believe Summit Therapeutics is more favorable than SpringWorks Therapeutics.
Summit Therapeutics received 201 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. However, 71.62% of users gave SpringWorks Therapeutics an outperform vote while only 58.48% of users gave Summit Therapeutics an outperform vote.
Summit Therapeutics has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -134.73%. SpringWorks Therapeutics' return on equity of -46.74% beat Summit Therapeutics' return on equity.
4.6% of Summit Therapeutics shares are owned by institutional investors. 7.6% of SpringWorks Therapeutics shares are owned by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
SpringWorks Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.04, suggesting that its stock price is 204% less volatile than the S&P 500.
Summary
SpringWorks Therapeutics and Summit Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get SpringWorks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SpringWorks Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SWTX) was last updated on 3/25/2025 by MarketBeat.com Staff
